Stem Cell Case Studies: Successes, Risks, and Emerging Trials

Stem cells are the body’s repair cells, able to turn into other cell types, and for decades the one proven use has been replacing a person’s blood and immune system. A handful of treatments are now routine or newly approved, many more are early experiments in a few dozen patients, and some sold directly to the public have caused blindness and death.¹² Whether a stem cell treatment is worth pursuing depends less on the cells themselves than on whether it is an established therapy, a registered trial, or a paid product with no evidence behind it.

Blood Stem Cell Transplants Are the Proven Success

In a blood stem cell transplant, often called a bone marrow transplant, a patient’s diseased blood system is wiped out and replaced with a donor’s blood-forming stem cells. The patient first gets chemotherapy, sometimes with radiation, to clear the old marrow. The donor cells then go in through a drip, much like a blood transfusion. Weeks in or near the hospital follow while the new cells settle in and start making blood, and the patient’s immune system is effectively rebuilt from the donor’s cells.

Among adults with acute myeloid leukemia treated this way, about 56% were alive five years later.³ In children with very high-risk leukemia, five-year survival after transplant rose to 65% for one type and 74% for another, up from about 28% and 34% in earlier years.⁴ Fewer patients now die of infection, treatment side effects, or the leukemia returning.⁵ In that study, results were good whether the donor was a sibling, an unrelated stranger, or a half-matched parent.⁶

Finding a donor is a real hurdle. Donors are matched on immune-system tissue markers, and a close match lowers the odds that donor cells will attack the patient’s body. A sibling has a decent chance of matching, but many patients have none and must turn to a registry of unrelated volunteers. Half-matched family donors, such as a parent or child, have widened access, so the lack of a perfect match no longer automatically rules out a transplant. How easy a match is to find can still vary with ancestry, because registries hold more volunteers from some backgrounds than others.

Children did better when transplanted in first remission, before the disease advanced.⁷ In Sweden, eight-year survival after leukemia was 65% for patients under 30.⁸ Among middle-aged patients, the region that transplanted twice as often saw eight-year survival of 51% versus 30% elsewhere, though such regional comparisons can’t prove the transplants alone made the difference.⁹ So if you or a relative has high-risk leukemia, asking early whether a transplant is an option can matter. Clinics often borrow the words “stem cell” to sound like this proven therapy, but a transplant replaces a whole blood system and has been tested in thousands of patients over decades.

Gene-Edited Stem Cells for Sickle Cell Disease

Doctors collect a patient’s own blood stem cells, edit them with the gene tool CRISPR to turn back on the fetal form of hemoglobin, and return them.¹⁰ In the first two patients, one with sickle cell and one with a transfusion-dependent blood disorder called beta-thalassemia, both stopped needing transfusions, and the sickle cell patient’s pain crises stopped.¹¹ In a larger group, 29 of 30 sickle cell patients went at least a year without a pain crisis, and none needed hospital care for one.¹² Because the cells come from the patient, there is no donor match to find and no risk of donor cells attacking the body.

The process takes patience. The stem cells are collected through a machine that filters them from the blood, then sent to a lab for editing, which takes weeks to months. Sickle cell patients’ stem cells can be harder to harvest, so the collection sometimes has to be repeated if too few healthy cells are gathered. After chemotherapy, the edited cells are infused by drip, and patients stay in the hospital for weeks until blood counts recover.

That chemotherapy is still part of the deal. Patients get strong doses to make room for the edited cells, and it carries infection and fertility risks.

Restoring Sight With Stem Cells

Burns or injuries can destroy the stem cells that keep the clear front of the eye renewed, leaving it cloudy.¹³ Growing a patient’s remaining stem cells in the lab and grafting them back restored a clear, self-renewing surface in about 77% of eyes.¹⁴ Failures showed up in the first year, and eyes that succeeded stayed stable for up to 10 years.¹⁵

This works where it does because some healthy stem cells are left to grow in the lab, usually in the other eye or a spared patch of the injured one. If both eyes are badly damaged, doctors have to rely on donor-derived cells, which brings back the problem of immune rejection. The treatment is for a specific condition, a loss of corneal stem cells, not for general cloudy vision or common age-related eye problems.

Macular degeneration kills a layer of support cells under the retina, and lab-made replacement sheets are being tested.¹⁶ In two patients, a patch made from embryonic stem cells improved vision by 29 and 21 letters on the eye chart over a year.¹⁷ In one patient, a sheet made from his own reprogrammed skin cells survived four years with stable vision and no further eye injections.¹⁸ In another small trial, grafts survived in everyone, yet only one patient showed meaningful vision gains, and one had a suspected immune reaction.¹⁹ These early trials mainly check safety and whether the graft survives, and larger trials comparing the patch with standard care are still needed.

The trials also differ from what clinics offer. Trial cells are grown into a specific retina cell type and placed surgically. Clinic injections often use fat-derived cells with no evidence behind them, and the blindness cases at unproven clinics came from eye injections.²⁰

Parkinson’s, Diabetes, and MS in Trials

Scientists can now turn ordinary adult cells into stem cells and grow them into almost any cell type.²¹ In a Japanese trial, brain cells grown this way and placed in the brains of people with Parkinson’s survived, made dopamine, and formed no tumors.²² That followed monkey studies in which the grafts improved movement for two years without tumors.²³

Parkinson’s involves the loss of dopamine-making brain cells, so the idea is to put new ones in the area where they were lost. What the trial reported, cells surviving, making dopamine and causing no tumors, are safety and function findings, not proof that patients’ daily symptoms improved. Only a small number of people have been treated and followed for a limited time, so long-term safety is still unknown.

In type 1 diabetes, 10 of 12 people given lab-grown insulin-making islets no longer needed insulin shots after a year.²⁴ The immune system destroys the insulin-making cells in the pancreas, so replacing them could in principle free people from injections. The group was small and followed for a year, so the result can’t say how long the cells will last. If the cells come from someone else, the patient may need drugs to keep the immune system from destroying them, and the original autoimmune attack could return.

For relapsing MS that keeps flaring despite standard drugs, a transplant using the patient’s own blood stem cells can reboot the immune system.²⁵ Most such patients go into lasting remission, with fewer relapses than on standard drugs and a low death rate from treatment at experienced centers, though the chemotherapy involved carries real risks.²⁶ Compared with a strong MS drug, alemtuzumab, transplant patients improved more in disability and thinking.²⁷ In people with active progressive MS, transplant delayed worsening of disability compared with standard drugs.²⁸ If your MS keeps relapsing despite treatment, you can ask a neurologist whether you qualify.

Knee and Heart Injections Fall Short

Knee injections use cells usually taken from bone marrow or fat, which calm inflammation and release growth signals.²⁹ Pain and movement improved over the first few months in one group of patients.³⁰ By two years, though, pain had crept back close to where it started, and some knees moved worse than before.³¹ Some studies report cartilage regrowth seen on scans or by camera inside the knee.³²

These results are hard to interpret. Knee arthritis pain naturally rises and falls, so improvement over a few months can reflect that, especially in people who expect to feel better. Studies with a comparison group, ideally a placebo injection, are the best way to tell real benefit from expectation. Pain relief and cartilage regrowth are also different questions: new tissue on a scan doesn’t always mean the knee feels or works better.

It also helps to know what is in the syringe. Bone marrow and fat contain only a small number of true stem cells among many other cell types, so a product is often a mixture rather than a purified stem cell dose. Preparations differ widely between clinics and studies, which makes results hard to compare and repeat. Cells taken from the patient and injected the same day are a different product from cultured or donor cells, and the rules about each differ.

Before paying for a knee injection, ask what kind of cells are used and where they come from, and what results look like after two years rather than two months. Ask whether it’s a registered trial or a cash product, and how the cost compares with physical therapy or knee replacement.

The heart has fared worse. Pooled trials found stem cells after a heart attack didn’t shrink the damaged area or improve pumping strength.³³ Few injected cells stay in the heart, and fewer still become heart muscle.³⁴ No one agrees on the best cell type, dose, or timing.³⁵

Risks Even in Legitimate Treatment

In graft-versus-host disease, the donor’s immune cells attack the patient’s skin, gut, or liver. After unrelated-donor transplants, about half of patients developed the early form and about 27% the long-term form.³⁶ Risk rose with poorer tissue matches, total-body radiation, and having the early form first.³⁷

For a patient, the early form often appears within the first months as a skin rash, diarrhea, or liver trouble such as yellowing of the skin or eyes. The long-term form can resemble an autoimmune disease, causing dry eyes, dry mouth, skin tightening, or joint stiffness. Reporting symptoms early matters because doctors can treat the problem more easily when it is caught soon.

There is a trade-off. Donor immune cells that attack the body can also attack leftover leukemia cells, so doctors aim for balance rather than removing all donor activity. Drugs that suppress the donor cells reduce the harm but can raise the chance of infection or relapse, and doctors adjust treatment to each patient.

Lab-made stem cells carry a different risk. Any stem cells left unconverted in a lab-made product can grow into tumors.³⁸ In mice, a small dose of leftover lab-made stem cells given into a vein was enough to cause tumors.³⁹ Trials screen cells carefully, which is part of why the Parkinson’s results without tumors matter.

The Dangers of Unproven Stem Cell Clinics

One review counted 35 cases of serious complications or deaths after unproven stem cell treatments.⁴⁰ The harms included partial or complete blindness in 9 people, blood clots in the lungs in 6, cardiac arrest in 5, and tumors or growths in 16.⁴¹ One person was left paraplegic, and some died of organ failure.⁴² Some injuries came from the cells themselves, not just the procedure.⁴³

Even harmless cells can do damage through the procedure. Injecting cells into the eye, spine, or bloodstream carries risks of infection, bleeding, and blocked vessels regardless of the cell type. Products made without strict sterile controls can be contaminated with bacteria, and a procedure done in a clinic without hospital emergency support can be harder to rescue when something goes wrong. Some warning signs: a clinic treats many unrelated diseases with the same cells, charges patients to take part, relies on testimonials rather than published results, or promises cures or no risk.

How to Find a Legitimate Trial

Real trials are listed on public registries such as ClinicalTrials.gov, and Japan’s trials carry registry numbers like jRCT.⁴⁴ Search the registry for your condition plus “stem cell,” then check the trial’s location and entry rules. Ask your specialist or a university hospital whether you’re eligible.

A listing tells you a lot if you know how to read it. It gives the trial’s phase, which shows how early it is: phase 1 mainly tests safety, while later phases test whether it works. It lists who can enter, such as age, disease stage, and previous treatments, so you can see whether you might qualify before contacting anyone. It also names the sponsor and the sites, so you can see whether a hospital or university is running it.

A registry listing alone isn’t enough, since some clinics list paid studies to look official. Check that a hospital or university runs the trial, and ask who pays and what happens if you’re harmed.

Benefit isn’t guaranteed, and in later-stage trials you may get a placebo. Expect frequent visits and scans, and know that you can leave at any time.